25E-NBOMe
25E-NBOMe is the N-(2-methoxybenzyl) analogue of 2C-E, a highly potent 5-HT2A agonist psychedelic. Active in the microgram-to-sub-milligram range and orally inactive, it shares the NBOMe series' steep dose-response curve, strong vasoconstriction and seizure risk.
01 Overview
25E-NBOMe is a comparatively obscure member of the 25x-NBOMe family that has appeared on blotter research-chemical markets. It has been detected in seizures and forensic samples across Europe.
Human pharmacology is uncharacterised; available information is anecdotal and forensic. Its 2C-E parentage suggests a longer, more introspective psychedelic character, but the NBOMe modification imposes the same narrow margin and cardiovascular/neurological toxicity as the rest of the class.
02 Mechanism
High-efficacy agonist at 5-HT2A receptors; the N-2-methoxybenzyl group increases 5-HT2A affinity by roughly two orders of magnitude over parent 2C-E.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Threshold | 150–400 µg | Sublingual | Estimated; sparse human data. |
| Common | 400–1200 µg | Sublingual | Anecdotal ranges; long duration expected. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Long psychedelic experienceVisuals and cognitive alteration reported as longer and more introspective than 25I-NBOMe, consistent with the 2C-E backbone. | 8-12 h | Anecdotal | |
| Stimulation and body loadMuscle tension, tremor and restlessness typical of the NBOMe series. | marked | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Severe vasoconstrictionCold extremities, hypertension and tachycardia. | Severe | Common | Anecdotal | |
| Seizures and serotonergic crisisOverdose can produce agitation, hyperthermia, seizures and rhabdomyolysis. | Life-threatening | Uncommon | Anecdotal |